As the IPO market continues to speed along, the fear is that weaker companies getting out at inflated prices will soon spoil the party. One crossover investor says this would be avoided if companies and banks use existing tools to find true market-based prices both before and after the deal.

BioCentury spoke with RA Capital's Peter Kolchinsky about the unusual debut of RNAi company Dicerna Pharmaceuticals Inc., in which underwriters Jefferies; Leerink Partners; Stifel, Nicolaus; and Baird agreed to forgo the usual lockup.